Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC)-The hunt for effective treatments
- PMID: 38531430
- DOI: 10.1016/j.jinf.2024.106146
Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC)-The hunt for effective treatments
Conflict of interest statement
Declaration of Competing Interest OOY serves on the CytoDyn Scientific Advisory Board and is a scientific consultant (compensated in stock options and cash) for CytoDyn. OOY is co-founder and board member for CDR3 Therapeutics Corp (stock). OOY is on the Board of Directors for Applied Medical Inc (stock and cash). NBG serves on the CytoDyn Scientific Advisory Board with stock option.
Comment on
-
Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis.J Infect. 2024 Feb;88(2):77-88. doi: 10.1016/j.jinf.2023.12.004. Epub 2023 Dec 13. J Infect. 2024. PMID: 38101521
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical